Tandem Diabetes Care Has Signed A Multi-Year Collaboration Agreement With The University Of Virginia Center For Diabetes Technology To Advance Research And Development Efforts On Fully Automated Closed-Loop Insulin Delivery Systems
Tandem Diabetes Care Has Signed A Multi-Year Collaboration Agreement With The University Of Virginia Center For Diabetes Technology To Advance Research And Development Efforts On Fully Automated Closed-Loop Insulin Delivery Systems
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.
Tandem Diabetes Care, Inc.（納斯達克：TNDM）是一家領先的胰島素輸送和糖尿病科技公司，今天宣佈與弗吉尼亞大學糖尿病科技中心（UVA）簽署了一項爲期多年的合作協議，以促進全面自動閉環胰島素輸送系統的研究和開發工作。
The research collaboration will rely on the UVA Center for Diabetes Technology's groundbreaking work to improve care for patients with diabetes through technology-based interventions, and its successes in translating advanced automated insulin delivery (AID) algorithms into medical devices used around the world, as well as Tandem's market leading expertise in insulin delivery devices, algorithm implementation, and data management.
該研究合作將依賴於UVA糖尿病科技中心在通過基於科技的干預措施改善糖尿病患者護理方面的開創性工作，以及在將愛文思控股的自動胰島素輸送（AID）算法轉化爲全球使用的醫療設備方面的成功，同時也將結合Tandem在胰島素輸送設備、算法實施和數據管理方面的行業領先專業知識。
The collaboration will expand on Tandem's ongoing research into the advancement of automated closed-loop insulin delivery technology, and will involve scientists, clinicians, and functional experts from both institutions. Results from this collaboration may lead to clinical research to accelerate approved uses for Tandem's next-generation AID systems.
此次合作將擴展Tandem在自動閉環胰島素輸送科技進步方面的持續研究，並將涉及來自雙方機構的科學家、臨牀醫生和功能專家。該合作的成果可能會導致臨牀研究，以加快Tandem下一代AID系統的批准使用。
譯文內容由第三人軟體翻譯。
